Wegovy And Zepbound Cost Effective But They Could Break Drug Budgets
ICER finds semaglutide and tirzepatide cost-effective for obesity but flags major affordability concerns and limited patient access at current prices. read more
Read More
Producer Inflation Tumbles–And Wall Street Sets New Record Highs
U.S. producer inflation drops in August, fueling hopes for Fed rate cuts as Wall Street reaches new highs. Pre-market trading shows S&P 500, Nasdaq 100 set for record highs. read more
Vivek Ramaswamy’s Strive To Board The Bitcoin Treasury Company With $1.5 Billion Raise
Asset Entities Inc. (NASDAQ:ASST) on Wednesday announced it has approved the company’s merger with Vivek Ramaswamy read more
A Glimpse Into The Expert Outlook On Coty Through 14 Analysts
Latest Ratings for COTY Date Firm Action From To Jan 2022 Raymond James Maintains Outperform Jan 2022 DA Davidson Upgrades Neutral Buy Jan 2022 Morgan Stanley Maintains Equal-Weight View More Analyst Ratings for COTY View the Latest Analyst Ratings read more
A Glimpse Into The Expert Outlook On PNC Financial Services Gr Through 9 Analysts
Latest Ratings for PNC Date Firm Action From To Jan 2022 Raymond James Maintains Outperform Jan 2022 Credit Suisse Maintains Neutral Jan 2022 JP Morgan Maintains Overweight View More Analyst Ratings for PNC View the Latest Analyst Ratings read more
Assessing SoFi Technologies: Insights From 14 Financial Analysts
Latest Ratings for SOFI Date Firm Action From To Mar 2022 Piper Sandler Initiates Coverage On Neutral Mar 2022 Morgan Stanley Maintains Overweight Mar 2022 Credit Suisse Maintains Neutral View More Analyst Ratings for SOFI View the Latest Analyst Ratings read more
Where Ameresco Stands With Analysts
Latest Ratings for AMRC Date Firm Action From To Mar 2022 B of A Securities Maintains Buy Mar 2022 Stifel Maintains Buy Mar 2022 Raymond James Maintains Outperform View More Analyst Ratings for AMRC View the Latest Analyst Ratings read more
Analyst Expectations For Lands’ End’s Future
Latest Ratings for LE Date Firm Action From To Jan 2021 Craig-Hallum Upgrades Hold Buy Feb 2017 Craig-Hallum Downgrades Buy Hold Sep 2016 CL King Downgrades Buy Neutral View More Analyst Ratings for LE View the Latest Analyst Ratings read more
